ROIV news

Roivant and Priovant announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis, setting the stage for a potential new treatment that could challenge existing systemic therapies.

Roivant reported positive data from a Phase 2 study of mosliciguat, showing significant improvements in pulmonary vascular resistance and other clinical endpoints, with new enrollment underway for a Phase 3 study. The company expects to present results at the European Respiratory Society Internation…

Roivant reported Q1 2026 results, highlighting a $3.9B cash balance and a settlement with Moderna.

Roivant reported strong cash position of $4.3 billion and progress across pipeline including IMVT-1402 showing positive rheumatoid arthritis data, brepocitinib Breakthrough Therapy designation, and a $2.25 billion Moderna settlement. The company expects multiple clinical readouts and a commercial la…